Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock

doi:10.4240/wjgs.v11.i12.422

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8459)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

573

WORD

265

HTML

4561

Figures (1-3)

414

Tables (1-4)

350

Sum=6163

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

979

Download

1317

Sum=2296

Dec 27, 2019 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Dec 27, 2019; 11(12): 422-432
Published online Dec 27, 2019. doi: 10.4240/wjgs.v11.i12.422

Table 1 Baseline patient characteristics in propensity-matched groups

	PMX-HP (n = 20)	Control (n = 20)	P value
Age, yr	66.7 ± 9.9	67.8 ± 10.2	0.719
Sex, Male, n (%)	12 (60.0)	12 (60.0)	1.000
Underlying malignancy, n (%)	11 (55.0)	12 (60.0)	0.749
Pre-existing organ dysfunction, n (%)	13 (65.0)	13 (65.0)	1.000
Liver insufficiency	1 (5.0)	0 (0.0)	0.311
Chronic respiratory disorder	1 (5.0)	5 (25.0)	0.077
Chronic heart failure	0 (0.0)	2 (10.0)	0.147
Chronic hemodialysis	3 (15.0)	1 (5.0)	0.292
Immunocompromised	3 (15.0)	0 (0.0)	0.072
Use of vasoactive agents
Norepinephrine	18 (90.0)	16 (80.0)	0.376
Dopamine	3 (15.0)	9 (45.0)	0.038
Dobutamine	2 (10.0)	0 (0.0)	0.147
Vasopressin	10 (50.0)	1 (5.0)	0.001
Epinephrine	6 (30.0)	5 (26.3)	0.798
Disease severity
SOFA score	11.2 ± 5.8	10.0 ± 4.0	0.446
APACHE II	19.1 ± 6.5	18.0 ± 4.4	0.534

Results are expressed in mean ± standard deviation; PMX-HP: Polymyxin B hemoperfusion; APACHE II: Acute physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment.

Table 2 Characteristics of patients, laboratory findings, and treatment of sepsis in propensity-matched groups

	PMX-HP (n = 20)	Control (n = 20)	P value
Primary infection site, n (%)			0.166
Upper GI tract	0 (0.0)	3 (15.0)
Small bowel	4 (20.0)	7 (35.0)
Lower GI tract	14 (70.0)	10 (50.0)
Hepatobiliary system	1 (5.0)	0 (0.0)
Soft tissue infection	1 (5.0)	0 (0.0)
Microorganisms, n (%)
Gram-negative species	11 (55.0)	10 (50.0)	0.752
Gram-positive species	6 (30.0)	7 (35.0)	0.736
Fungus	4 (20.0)	3 (15.0)	0.677
No growth	5 (25.0)	7 (35.0)	0.490
Number of microorganisms, n (%)			0.747
Single microorganism	9 (45.0)	7 (35.0)
Multiple microorganisms	6 (30.0)	6 (30.0)
Laboratory test on admission
WBC, 10⁹/L	87.6 ± 64.9	94.0 ± 49.1	0.731
Platelet counts, 10⁹/L	130.0 ± 102.0	163.7 ± 133.5	0.375
Hb, g/L	9.6 ± 2.0	10.5 ± 2.2	0.178
PT, %	45.7 ± 24.4	55.0 ± 16.5	0.168
Lactate, mmol/L	7.8 ± 6.9	7.2 ± 3.1	0.738
Methods of infection control, n (%)			1.000
Surgical intervention	19 (95.0)	19 (95.0)
Radiologic intervention	1 (5.0)	1 (5.0)
Other therapeutic management, n (%)
pRBC transfusion, n (%)	11 (55.0)	19 (95.0)	0.006
Mechanical ventilator	14 (70.0)	16 (80.0)	0.537
Re-intubation	3 (15.0)	2 (10.0)	0.633
RRT	9 (45.0)	8 (40.0)	0.749

GI: Gastrointestinal system; Hb: Hemoglobin; pRBC: Packed red blood cells; PT: Prothrombin tine; RRT: Renal replacement therapy; WBC: White blood cell count; PMX-HP: Polymyxin B hemoperfusion.

Table 3 Comparative analysis of variables changes between baseline and 72 h after treatment

Patients	PMX-HP (n = 20)		Control (n = 20)		P value
Patients	T_o¹	T₇₂²	T_o³	T₇₂⁴	P value
SOFA score	11.2 ± 5.8	4.7 ± 3.5	10.0 ± 4.0	8.7 ± 7.3	0.047^a
Respiratory SOFA	2.6 ± 1.0	1.9 ± 1.0	2.6 ± 1.5	1.8 ± 1.0	0.799
Cardiovascular SOFA	3.4 ± 1.2	0.4 ± 0.9	2.3 ± 1.8	1.2 ± 1.3	0.072
Liver SOFA	0.7 ± 0.9	1.1 ± 1.5	0.7 ± 1.3	1.4 ± 1.3	0.683
Renal SOFA	2.6 ± 1.0	0.7 ± 1.0	2.6 ± 1.5	2.8 ± 1.6	0.000^a
Coagulation SOFA	1.6 ± 1.5	1.3 ± 1.3	1.2 ± 1.2	2.8 ± 1.8	0.014^a
WBC, 10⁹/L	87.7 ± 65.0	102.5 ± 62.7	94.0 ± 49.1	115.6 ± 59.0	0.552
Hb, g/L	9.6 ± 2.0	9.0 ± 0.9	10.5 ± 2.2	9.7 ± 1.0	0.024^a
Inotropic score	163.7 ± 302.1	8.9 ± 19.1	90.8 ± 181.7	1.4 ± 4.2	0.006^a
VDI	2.4 ± 3.4	0.1 ± 0.3	1.0 ± 2.0	0.0 ± 0.1	0.001^a

¹Immediately after completion of two session of polymyxin B hemoperfusion (PMX-HP);

²Seventy-two hours after completion of two session of PMX-HP;

³Immediately after surgical control;

⁴Seventy-two hours after conventional standard therapy according to survival sepsis campaign.

^aP < 0.05, compared with variables between just before initiating treatment and 72 h after initiating the treatment in PMX-HP group and control group. SOFA: Sequential organ failure assessment; WBC: White blood cell; Hb: Hemoglobin; VDI: Vasopressor dependency index; PMX-HP: Polymyxin B hemoperfusion.

Table 4 Mortality, length of Intensive care unit stay and ventilator free days in polymyxin B hemoperfusion and control groups

	PMX-HP (n = 20)	Control (n = 20)	P value
ICU mortality (%)	4 (20)	8 (40)	0.168
28-d mortality (%)	9 (45)	8 (40)	0.749
In hospital mortality (%)	10 (50)	10 (50)	1.000
Length of ICU stay (d)	10.9 ± 3.9 (5-19)	14.6 ± 6.4 (5-23)	0.036
Mechanical ventilator days (d)	5.1 ± 4.7 (0-16)	4.9 ± 5.4 (0-18)	0.926

ICU: Intensive care unit; PMX-HP: Polymyxin B hemoperfusion.

Citation: Kim JJ, Park YJ, Moon KY, Park JH, Jeong YK, Kim EY. Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock. World J Gastrointest Surg 2019; 11(12): 422-432
URL: https://www.wjgnet.com/1948-9366/full/v11/i12/422.htm
DOI: https://dx.doi.org/10.4240/wjgs.v11.i12.422